Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDIntegra Lifesciences Holdings Corp Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 5 | $0.40 | $0.41 | $0.40 |
| Q2 2026 | 5 | $0.47 | $0.49 | $0.48 |
| Q3 2026 | 5 | $0.55 | $0.59 | $0.57 |
| Q4 2026 | 1 | $0.85 | $0.87 | $0.86 |
| Q1 2027 | 1 | $0.53 | $0.55 | $0.54 |
| Q2 2027 | 1 | $0.62 | $0.64 | $0.63 |
| Q3 2027 | 1 | $0.67 | $0.68 | $0.68 |
| Q4 2027 | 1 | $0.79 | $0.81 | $0.80 |
| Q1 2028 | 2 | $0.61 | $0.62 | $0.62 |
| Q2 2028 | 2 | $0.71 | $0.73 | $0.72 |
| Q3 2028 | 2 | $0.75 | $0.76 | $0.76 |
| Q4 2028 | 2 | $0.86 | $0.88 | $0.87 |
Integra Lifesciences Holdings Corp Earnings Date And Information
Integra Lifesciences Holdings Corp last posted its earnings results on Tuesday, May 5th, 2026. The company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.41 by $0.13. The company had revenue of 391.92 M for the quarter and had revenue of 1.64 B for the year. Integra Lifesciences Holdings Corp has generated $-7 earnings per share over the last year ($-6.73 diluted earnings per share) and currently has a price-to-earnings ratio of -2.31. Integra Lifesciences Holdings Corp has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Integra Lifesciences Holdings Corp Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/05/2026 | Q1 2026 | $0.41 | -$0.06 | -0.47 | $381.81 M | $391.92 M |
| 02/26/2026 | Q4 2025 | $0.79 | -$0.02 | -0.81 | $429.63 M | $434.93 M |
| 10/30/2025 | Q3 2025 | $0.43 | -$0.07 | -0.5 | $414.23 M | $402.06 M |
| 07/31/2025 | Q2 2025 | $0.43 | -$6.33 | -6.76 | $395.00 M | $415.61 M |
| 05/05/2025 | Q1 2025 | $0.43 | -$0.33 | -0.76 | $381.20 M | $382.65 M |
| 02/25/2025 | Q4 2024 | $0.86 | $0.25 | -0.61 | $445.11 M | $442.65 M |
| 11/04/2024 | Q3 2024 | $0.39 | -$0.14 | -0.53 | $375.81 M | $380.83 M |
| 07/29/2024 | Q2 2024 | $0.62 | -$0.16 | -0.78 | $413.07 M | $418.18 M |
| 05/06/2024 | Q1 2024 | $0.55 | -$0.04 | -0.59 | $363.74 M | $368.87 M |
| 02/28/2024 | Q4 2023 | $0.90 | $0.25 | -0.65 | N/A | $397.04 M |
| 10/25/2023 | Q3 2023 | $0.78 | $0.24 | -0.54 | N/A | $382.42 M |
| 07/27/2023 | Q2 2023 | N/A | $0.05 | N/A | N/A | $381.27 M |
| 04/26/2023 | Q1 2023 | $0.74 | $0.30 | -0.44 | N/A | $380.85 M |
| 02/22/2023 | Q4 2022 | $0.93 | $0.63 | -0.3 | N/A | $398.02 M |
| 10/26/2022 | Q3 2022 | $0.72 | $0.60 | -0.12 | N/A | $385.19 M |
| 07/27/2022 | Q2 2022 | $0.80 | $0.54 | -0.26 | N/A | $397.82 M |
| 04/27/2022 | Q1 2022 | $0.68 | $0.39 | -0.29 | N/A | $376.64 M |
| 02/24/2022 | Q4 2021 | N/A | $0.54 | N/A | N/A | $405.52 M |
| 11/02/2021 | Q3 2021 | $0.72 | $0.51 | -0.21 | N/A | $386.86 M |
| 07/29/2021 | Q2 2021 | N/A | $0.41 | N/A | N/A | $389.99 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Integra Lifesciences Holdings Corp Earnings: FAQ's
In the previous quarter, Integra Lifesciences Holdings Corp (:IART) reported $0.54 earnings per share (EPS) to beat the analysts' consensus estimate of $0.41 by $0.13.
The conference call for Integra Lifesciences Holdings Corp's latest earnings report can be listened to online.
The conference call transcript for Integra Lifesciences Holdings Corp's latest earnings report can be read online.
Integra Lifesciences Holdings Corp (:IART) has a recorded annual revenue of $1.64 B.
Integra Lifesciences Holdings Corp (:IART) has a recorded net income of $-516,474,000.Integra Lifesciences Holdings Corp has generated $-6.73 earnings per share over the last four quarters.
Integra Lifesciences Holdings Corp (:IART) has a price-to-earnings ratio of -2.31 and price/earnings-to-growth ratio is 0.